Supplementary File S4

Table 1 Number and percentage of undetectable values excluded from regression and Spearman's correlation analyses, stratified by disease severity.

Validation Cohort (ddPCR measurement)	**PwoMS (n=23)**	**Low-EDSS PwMS (n=24)**	**High-EDSS PwMS (n=24)**
	n undetectable (%)	**n undetectable (%)**	**n undetectable (%)**
hsa-miR-26b-5p	0 (0%)	0 (0%)	0 (0%)
hsa-miR-181d-5p	0 (0%)	0 (0%)	0 (0%)
ebv-miR-BART11-5p	3 (13.0%)	5 (20.8%)	2 (8.3%)
ebv-miR-BART1-5p	13 (56.5%)	16 (66.7%)	10 (41.7%)
ebv-miR-BART2-5p	13 (56.5%)	11 (45.8%)	11 (45.8%)
ebv-miR-BART20-5p	9 (39.1%)	12 (50%)	8 (33.3%)
ebv-miR-BHRF1-3	15 (65.2%)	14 (58.3%)	18 (75%)
EBNA1 DNA	4 (17.4%)	4 (16.6%)	6 (25.0%)
EBER1 DNA	3 (13.4%)	4 (16.6%)	6 (25.0%)

Table 2 Number and percentage of undetectable values excluded from regression analysis, stratified by treatment status.

Validation Cohort ddPCR measurement	**PwoMS (n=23)**	**Non-BCDT-treated PwMS (n=20)**	**BCDT-treated PwMS (n=28)**
	n undetectable (%)	**n undetectable (%)**	**n undetectable (%)**
hsa-miR-26b-5p	0 (0%)	0 (0%)	0 (0%)
hsa-miR-181d-5p	0 (0%)	0 (0%)	0 (0%)
ebv-miR-BART11-5p	3 (13.0%)	2 (8.3%)	5 (20.8%)
ebv-miR-BART1-5p	13 (56.5%)	13 (65.0%)	13 (46.4%)
ebv-miR-BART2-5p	13 (56.5%)	11 (55.0%)	11 (39.3%)
ebv-miR-BART20-5p	9 (39.1%)	10 (50.0%)	10 (35.7%)
ebv-miR-BHRF1-3	15 (65.2%)	14 (70.0%)	18 (64.3%)
EBNA1 DNA	4 (17.4%)	2 (10.0%)	8 (28.6%)
EBER1 DNA	3 (13.4%)	2 (10.0%)	8 (28.6%)